Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-20T04:32:05.075Z Has data issue: false hasContentIssue false
  • English
  • Français

Successful treatment of intranasal papillomata with imiquimod cream in a human immunodeficiency virus positive patient

Published online by Cambridge University Press:  19 May 2008

A Fernández-Casado ,
R M Pujol ,
M Amat  and
F Gallardo
A Fernández-Casado
Affiliation:
Department of Dermatology, Hospital del Mar-IMAS (Institut Municipal d'Assistència Sanitària), Barcelona, Spain
R M Pujol*
Affiliation:
Department of Dermatology, Hospital del Mar-IMAS (Institut Municipal d'Assistència Sanitària), Barcelona, Spain
M Amat
Affiliation:
Department of Otorhinolaryngology, Hospital del Mar-IMAS (Institut Municipal d'Assistència Sanitària), Barcelona, Spain
F Gallardo
Affiliation:
Department of Dermatology, Hospital del Mar-IMAS (Institut Municipal d'Assistència Sanitària), Barcelona, Spain
*
Address for correspondence: Dr Ramon M Pujol, Department of Dermatology, Hospital del Mar-IMAS, Passeig Marítim 25-29, 08003 Barcelona, Spain. Fax: 0034 932483328 E-mail: rpujol@imas.imim.es
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To report a new, alternative treatment for nasal papillomata in human immunodeficiency virus positive patients with multiple recurrences after surgical removal.

Case report:

A human immunodeficiency virus positive patient presented with multiple, recurrent nasal papillomata which developed after repeated surgical removal procedures. In this patient, complete and persistent resolution of the lesions was achieved after topical treatment with imiquimod cream.

Conclusion:

Imiquimod is a class of non-nucleoside imidazoquinolinamines which promotes local cytokine release from antigen-presenting cells inducing a T-h1 dominant cell-mediated response against virus-infected cells. Topical imiquimod 5 per cent cream, applied for four to 16 weeks, may offer some benefit in the management of recurrent nasal papillomata in human immunodeficiency virus positive patients. Such treatment may be preferable to surgery or destructive therapeutic options when patients are unwilling or are poor surgical candidates, and also avoids potential surgical sequelae such as scar formation and stenosis.

Keywords

ImiquimodPapillomaNasal CavityHIV
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 2 , February 2009 , pp. 240 - 242
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Shanmugaratnam, K, Sobin, LH. Histological Typing of Tumours of the Upper Respiratory Tract and Ear. Berlin: Springer Verlag, 1991CrossRefGoogle Scholar
2Bouscarat, F, Mahe, E, Descamps, V. External anogenital condylomas. Ann Dermatol Venereol 2002;129:1013–22Google ScholarPubMed
3Halvorson, DJ, Kuhn, FA. Intranasal presentation of condyloma acuminatum. Otolaryngol Head Neck Surg 1996;114:113–15CrossRefGoogle ScholarPubMed
4Drake, LA, Ceily, R, Cornelison, RL, Dobes, WL, Dorner, W, Goltz, RW et al. Guidelines of care for warts: human papillomavirus. J Am Acad Dermatol 1995;32:98–103Google ScholarPubMed
5Phillips, P, Gustafson, R, Facer, G. The clinical behaviour of inverting papilloma of the nose and paranasal sinuses. Laryngoscope 1990;100:463–9CrossRefGoogle ScholarPubMed
6Kumagai, M, Endo, S, Matsunaga, E, Kida, A, Sakata, H, Yamamoto, M. Squamous papillomatosis of the bilateral nasal cavities. Tohoku J Exp Med 2005;206:267–70CrossRefGoogle ScholarPubMed
7Hengge, UR, Ruzicka, T. Topical immunomodulation in dermatology: potential of Toll-like receptor agonists. Dermatol Surg 2004;30:1101–12Google ScholarPubMed
8Kaspari, M, Gutzmer, R, Kaspari, T, Kapp, A, Brodersen, JP. Application of imiquimod by suppositories (anal tampons) prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 2002;147:757–9CrossRefGoogle ScholarPubMed
9Jorizzo, J, Dinehart, S, Matheson, R, Moore, JK, Ling, M, Fox, TL et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57:265–8CrossRefGoogle ScholarPubMed
10Arlette, JP, Trotter, MJ. Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment. Australas J Dermatol 2004;45:1–11CrossRefGoogle ScholarPubMed
11Harwood, CA, Perret, CM, Brown, VL, Leigh, IM, McGregor, JM, Proby, CM. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosupressed individuals. Br J Dermatol 2005;152:122–9CrossRefGoogle Scholar
12Juschka, U, Hartmann, M. Topical treatment of common warts in an HIV-positive patient with imiquimod 5% cream. Clin Exp Dermatol 2003;28(suppl 1):48–50CrossRefGoogle Scholar
13Caversaccio, M, Aebi, S. Medical treatment of nasal squamous papilloma with imiquimod cream. J Laryngol Otol 2003;117:720–2CrossRefGoogle ScholarPubMed
14Heard, I, Plalefsky, JM, Kazatchkine, MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004;9:13–22CrossRefGoogle ScholarPubMed